Table 2. Univariate analyses of clinical prognostic factors (P-values).
|
Disease-free survival
|
Overall survival
|
||||
|---|---|---|---|---|---|
| Factors | Number of patients | RR of relapse and 95% CI | P-value | RR of dying and 95% CI | P-value |
| TS | 0.712 | 0.153 | |||
| <25 | 77 | 1 | 1 | ||
| ⩾25 | 74 | 0.927 (0.620–1.387) | 0.725 (0.467–1.127) | ||
| TP | 0.10 | 0.043 | |||
| <25 | 66 | 1 | 1 | ||
| ⩾25 | 85 | 0.714 (0.477–1.070) | 0.638 (0.413–0.986) | ||
| ERCC1 | 0.060 | 0.051 | |||
| <17.5 | 65 | 1 | 1 | ||
| ⩾17.5 | 86 | 0.677 (0.451–1.017) | 0.644 (0.414–1.001) | ||
| EGFR PharmDx | 0.115 | 0.045 | |||
| Negative | 29 | 1 | 1 | ||
| 1+ to 3+ | 113 | 0.676 (0.415–1.101) | 0.605 (0.370–0.988) | ||
| ARK1 | 0.139 | 0.297 | |||
| Negative | 45 | 1 | 1 | ||
| Positive | 96 | 1.385 (0.899–2.134) | 0.791 (0.509–1.229) | ||
| ARK2 | 0.101 | 0.067 | |||
| Negative | 46 | 1 | 1 | ||
| Positive | 104 | 0.712 (0.474–1.069) | 0.678 (0.448–1.028) | ||
| EGFR FISH | 0.775 | 0.440 | |||
| Negative | 111 | 1 | 1 | ||
| Positive | 18 | 0.918 (0.510–1.652) | 0.779 (0.413–1.469) | ||
Abbreviations: ARK=aurora kinase; CI=confidence interval; EGFR=epidermal growth factor receptor; ERCC1=excision repair cross-complementing gene 1; TP=thymidine phosphorylase; TS=thymidylate synthase; RR=relative risk.
Relative risk adjusted for stage. If the relative risk is >1, the relative risk can be thought as the average increased risk of relapse or dying compared with the reference group. The group with the ratio equal to 1 is the reference group.